Add semaglutide to the mix and the decline accelerates
While compounded versions of Tirzepatide will soon no longer be available per the U.S
For multi-dose pens like Ozempic, perform a flow check only before the first use of each new pen, not before every injection
In the United States, FDA guidelines indicate these medications for: Adults with a BMI of 30 or higher (obesity) Adults with a BMI of 27 or higher who also have at least one weight-related health condition, such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea You should discuss GLP-1 medications with a physician if you have any of the following, as they may affect which medication is appropriate or require additional monitoring: Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) a contraindication for all GLP-1 drugs History of pancreatitis Kidney disease or a history of gallstones Pregnancy or plans to become pregnant History of eating disorders The Critical Factor Most People Overlook: Muscle Loss Here is something that rarely appears in GLP-1 marketing: these medications can cause significant muscle loss alongside fat loss, particularly at the aggressive weight loss rates they enable
The role of semaglutide treatment
Another reasonable scenario involves patients who experience a pronounced rollercoaster effect, severe symptoms for the first 48-72 hours followed by complete loss of appetite suppression by day six or seven
